Changeflow GovPing Healthcare & Life Sciences Patent Application: Cancer Treatment Compositio...
Routine Notice Added Draft

Patent Application: Cancer Treatment Compositions and Methods

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO has published a patent application (US20260085074A1) detailing compositions and methods for treating cancer by modulating K-Ras, a frequently mutated oncogene. The application was filed on June 17, 2025, by inventors Jonathan Ostrem, Ulf Peters, and Kevan M. Shokat.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application from the USPTO for "Compositions and Methods for Treating Cancer." The application, filed on June 17, 2025, by inventors Jonathan Ostrem, Ulf Peters, and Kevan M. Shokat, specifically discloses compositions and methods for modulating K-Ras, identified as the most frequently mutated oncogene in human cancer, with the aim of treating cancer.

As this is a patent application, it represents a disclosure of potential new intellectual property rather than a regulatory requirement. Companies in the pharmaceutical and biotechnology sectors involved in oncology research and development may find the disclosed compositions and methods of interest for potential licensing, collaboration, or competitive analysis. No immediate compliance actions or deadlines are imposed by a patent application itself.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

COMPOSITIONS AND METHODS FOR TREATING CANCER

Application US20260085074A1 Kind: A1 Mar 26, 2026

Inventors

Jonathan Ostrem, Ulf Peters, Kevan M. Shokat

Abstract

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

CPC Classifications

C07D 495/04 A61K 38/1709 C07C 235/20 C07C 317/08 C07D 207/14 C07D 211/58 C07D 211/62 C07D 231/40 C07D 295/185 C07D 295/26 C07D 401/04 C07D 401/06 C07D 401/12 C07D 405/12 C07D 409/04 C07D 413/12 C07D 417/12 C07D 471/10 C07D 487/04 C07D 487/10 C12N 9/14 C12Q 1/6886 C12Q 2600/156 C12Q 2600/158 C12Y 306/05002 G01N 2500/04

Filing Date

2025-06-17

Application No.

19241185

View original document →

Named provisions

Inventors Abstract CPC Classifications

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
June 17th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260085074A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Cancer Treatment
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Topics
Drug Development Oncology

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!